Anixa Biosciences Inc (ANIX)
2025-07-31 | 2025-04-30 | 2024-07-31 | ||
|---|---|---|---|---|
| Revenue | - | - | - | |
| Research and development expenses (including non-cash stock-based compensation expenses of 358, 462, 1,172 and 1,471, respectively) | 1,055 | 1,322 | 1,925 | |
| General and administrative expenses (including non-cash stock-based compensation expenses of 497, 717, 1,727 and 2,228, respectively) | 1,381 | 1,681 | 1,667 | |
| Total operating expenses | 2,436 | 3,003 | 3,592 | |
| Loss from operations | -2,436 | -3,003 | -3,592 | |
| Interest income | 156 | 190 | 277 | |
| Net loss | -2,280 | -2,813 | -3,315 | |
| Less net loss attributable to noncontrolling interest | -22 | -23 | -38 | |
| Net loss attributable to common shareholders | -2,258 | -2,790 | -3,277 | |
| Basic | -0.07 | -0.09 | -0.1 | |
| Basic | 32,476,000 | 32,202,000 | 32,054 | |
| Diluted | -0.07 | -0.09 | -0.1 | |
| Diluted | 32,476,000 | 32,202,000 | 32,054 | |